Semaglutide does not have one U.S. price. Ozempic and Wegovy contain semaglutide, but each product family includes specific tablet or injection presentations, distinct FDA-labeled purposes and different pathways to payment. Comparing a promotional pen offer with an oral tablet list price can give an entirely misleading picture of cost.
Start by identifying the exact prescribed brand, form, strength and package quantity; then distinguish a manufacturer list price from a pharmacy cash quote, a limited self-pay program and what an insurer actually leaves you owing. Our U.S. product-identification guide covers the first step, while Ozempic-versus-Wegovy cost comparisons address a narrower pairwise question.
This guide explains a reliable comparison method and the available payment categories without pretending that there is a universal live market quote. Program details may change or expire; verify any number against the official manufacturer terms, a legitimate dispensing pharmacy and your own plan before spending money.
Ozempic pen, Ozempic tablets, Wegovy pens, Wegovy tablets and Wegovy HD are not interchangeable line items. A pen box, a four-pen Wegovy pack and a bottle of oral tablets represent different labeled presentations and often different supply units. Strength, route of administration and brand can change the offer even when the active ingredient is the same.
The clinical indication also shapes insurance eligibility: an Ozempic prescription for a labeled type 2 diabetes use and a Wegovy prescription for a labeled weight-management use can be evaluated under different benefit categories. Product details are mapped on Ozempic and Wegovy.
List price is a published manufacturer benchmark, not a forecast of the patient bill. A retail cash quote is a pharmacy-specific offer for a precise product and supply. A manufacturer self-pay program is conditional and can have product, strength, eligibility and time limits. Insured out-of-pocket cost depends on the member benefit, deductible, formulary, network and copayment or coinsurance.
A coupon may reduce a qualifying payment without changing list price; a new-patient promotion may end before a second or third fill. The savings-program guide focuses on program restrictions rather than repeating this high-level comparison.
Use one record per actual prescribed presentation. The most informative comparison is the total price for the specified supply after checking eligibility, not a dollar-per-milligram ratio that encourages false equivalence among oral and injectable formulations.
The worksheet deliberately leaves real-time amounts to an official dated quote. Do not compare weight-management and diabetes prescriptions as though they were automatically eligible for the same insurance benefit.
| Product family | Supply basis to verify | Where pricing comes from | Important limitation |
|---|---|---|---|
| Ozempic injection | Specific pen product and labeled box | Manufacturer terms; licensed pharmacy; plan claim | Different from oral-tablet strength and pricing |
| Ozempic tablets | Bottle and tablet strength; commonly a 30-tablet supply | Official tablet offer; pharmacy; benefits | Tablets do not share pen dose equivalents |
| Wegovy standard injection | Specified 4-pen pack or labeled supply | Official injection offer; pharmacy; benefit | Limited promotions may apply only to select fills |
| Wegovy tablets | Specified bottle and tablet strength | Official oral-product offer; pharmacy; benefit | Oral administration and eligibility differ |
| Wegovy HD | 7.2-mg pen product and box | HD-specific offer and plan rules | Do not assume standard Wegovy price or eligibility |
Ask the prescriber or pharmacist to confirm the exact product and quantity; obtain the manufacturer offer terms with their date; ask a licensed pharmacy for the identical package; request a benefits estimate for the indication and network; and document which fees are included. An estimate without a package definition cannot establish which option is cheaper.
If prescription coverage is uncertain, consult insurance coverage by indication before comparing pharmacy cash quotes. When you are entirely uninsured or deliberately paying cash, legitimate self-pay pathways gives a separate action plan.
Official manufacturer terms offer concrete reference points, but these are not universal retail prices or insurance copays. As verified October 18, 2026, NovoCare describes Ozempic pill, Ozempic pen, Wegovy pill and Wegovy pen self-pay rates that vary by specific prescribed strength and whether a short introductory promotion applies. Do not compare an oral tablet bottle with an injection pen box as if their dosing were equivalent.
The amounts below refer to qualifying manufacturer self-pay pathways, not all U.S. pharmacies. The limited lower-strength pen introductory offers described here run through December 31, 2026 for eligible new patients and a restricted number of fills; manufacturer terms may be changed or withdrawn. Confirm the current published rate before payment.
| Exact product / scenario | Manufacturer-published amount as checked Oct 18, 2026 | Supply / limitations |
|---|---|---|
| Ozempic pill 1.5 / 4 / 9 mg | $149 / $199 / $299 per month, respectively | Qualifying 30-tablet bottle; eligibility and product terms |
| Ozempic pen 0.25 or 0.5 mg — eligible new patient | $199 per monthly fill for first two fills | Offer through Dec 31, 2026; subsequent rate differs |
| Ozempic pen 0.25, 0.5 or 1 mg | $349 per month after eligible introductory period | One qualifying pen box; applicable restrictions |
| Ozempic pen 2 mg | $499 per month | Qualifying pen box; not the lower-strength offer |
| Wegovy pill 1.5 / 4 / 9 or 25 mg | $149 / $199 / $299 per month, respectively | One qualifying bottle of 30 tablets |
| Wegovy pen 0.25 or 0.5 mg — eligible new patient | $199 per monthly fill for first two fills | Limited through Dec 31, 2026; qualifying fills |
| Wegovy standard pen 0.25–2.4 mg | $349 per month after eligible introductory period | Qualifying four-pen box |
| Wegovy HD 7.2 mg | $399 per month | Separate qualifying HD four-pen box |
The Ozempic pricing guide examines pen-versus-tablet options within one brand, including distinct pharmacy units and manufacturer offers. The Wegovy pricing guide covers tablets, ordinary injection pens and HD, without suggesting those versions are substitutable.
These dedicated pages are the appropriate place for granular product-specific terms. The role of this hub is to help you understand which types of quote can be compared fairly and to prevent an attractive displayed price from driving the wrong product choice.
A covered brand may still require prior authorization, quantity limits, step therapy or an in-network dispensing pharmacy. A plan may assess each form separately or cover a medicine for one medically accepted indication but not another. Approval for a prescription does not, by itself, mean the payer will pay for it.
For precise benefit questions use Ozempic insurance checks, Wegovy insurance checks or prior authorization procedures. A cash coupon can also be incompatible with an insurance claim or government-program coverage.
Medical consultations, ongoing follow-up, possible lab work, dispensing fees and shipping may add expenses not shown in a drug comparison chart. Not every patient needs the same monitoring, and a platform subscription may be payable whether or not a prescription is issued.
Build a complete expected expense worksheet with total treatment cost. Do not compare an all-inclusive clinic quote to a pharmacy-only medicine quote without separating their services.
An online listing promising prescription-free semaglutide or an unspecified generic is not made reliable by a low advertised price. FDA-approved prescription products must be distinguished from compounded preparations and from brands marketed in other countries that have not received U.S. approval.
Check U.S. generic status, compounding distinctions and pharmacy legitimacy before comparing any suspiciously inexpensive offer.
Manufacturer and pharmacy terms can change independently, so an offer captured last month may not describe today’s checkout. Record the date, official sponsor, product NDC or exact formulation, eligible member type and applicable restrictions for each candidate quote. A clear comparison contains these source attributes beside the value.
When a quote was presented by a third-party referral site, recheck the actual pharmacy or manufacturer before making a payment decision. The process of confirming a lawful dispenser is discussed in pharmacy verification steps.
Other prescription medicines used for diabetes or weight management may be relevant to a clinical discussion, but a price comparison with Mounjaro or Zepbound does not prove interchangeable labeling, treatment outcomes or dosage. Those are separate drug entities with their own package and payer criteria.
If the user is specifically comparing a different ingredient, continue to Ozempic versus Mounjaro costs or Wegovy versus Zepbound costs rather than extending this semaglutide-only grid.
First establish the clinically appropriate FDA-labeled product with a licensed prescriber. Next define the exact supply and determine whether coverage, manufacturer eligibility or cash payment applies. Only then ask dispensing pharmacies for comparable totals.
This site is an informational guide, not a pharmacy, prescriber or insurer. It may receive referral compensation where disclosed near an applicable commercial link; such relationships should never change the prescription and safety checks described here.
There is no single national monthly price. Brand, formulation, strength, package, insurance and time-limited savings terms all affect the bill. Verify a dated quote for the exact prescribed product.
Not necessarily. They are distinct products with separate presentations, labeled uses, benefit policies and offers. Sharing the active ingredient does not establish identical cost.
Usually not by itself. Deductibles, formulary design, negotiated pharmacy rates, manufacturer eligibility and other conditions may produce a different final amount.
No. Tablet and injection doses are not directly convertible on that basis; compare the prescribed package and covered supply rather than a crude per-milligram calculation.
No. Some promotions are limited by time, fills, strengths or eligibility. Always identify what happens after the initial qualifying supply.
No. Product authorization and pharmacy legitimacy must be checked independently of price. Suspicious prescription-free or imported listings may be unsafe or unlawful.
No. Coverage depends on plan, product, indication and authorization rules, and one brand or form may be treated differently from another.
Include clinical fees when comparing the full cost of care. Keep them separate from pharmacy medication prices so quotes remain comparable.
A benefits estimate can help, but actual patient liability may depend on the claim, plan status, pharmacy and current terms at dispensing.